Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MET-3 in Obese Subjects
NCT03660748Phase 1Completed
- Sponsor
- NuBiyota
- Start
- Oct 2018
- Primary completion
- Jan 2020
- Countries
- 1
01
Overview
Phase 1, open-label trial of MET-3 in obesity (2 arms), sponsored by NuBiyota. Primary endpoint: Incremental Area Under the Glucose Curve at 6 weeks. Started Oct 2018; status: completed.
02
Drugs
MET-3
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03660748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03660748.